Sand Hill Global Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.92M Sell
5,885
-484
-8% -$215K 0.09% 99
2026
Q1
$2.84M Buy
6,369
+1,193
+23% +$556K 0.1% 92
2025
Q4
$2.35M Sell
5,176
-1,550
-23% -$668K 0.08% 97
2025
Q3
$2.63M Sell
6,726
-594
-8% -$248K 0.09% 97
2025
Q2
$3.26M Buy
7,320
+395
+6% +$182K 0.12% 91
2025
Q1
$3.36M Buy
+6,925
New +$3.23M 0.14% 84

Other funds holding VRTX

Sand Hill Global Advisors's VRTX Position: Q2 2026 in Review

Sand Hill Global Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 7.6% in Q2 2026, selling an estimated $215K and leaving 5,885 shares worth $2.92M. The position accounts for 0.09% of the portfolio, ranked #99.

Sand Hill Global Advisors first reported a position in VRTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.36M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Sand Hill Global Advisors held 5,885 shares of Vertex Pharmaceuticals worth $2.92M as of Q2 2026.
  • Sand Hill Global Advisors sold 484 Vertex Pharmaceuticals shares in Q2 2026, an estimated $215K.
  • Vertex Pharmaceuticals made up 0.09% of Sand Hill Global Advisors's portfolio in Q2 2026, its #99 holding.
  • Sand Hill Global Advisors first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Sand Hill Global Advisors's Vertex Pharmaceuticals position peaked at $3.36M in Q1 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sand Hill Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.